Record interest in Nordic life science companies as 37 international investors meet at Nasdaq

Interest in Nordic life science companies is higher than in a very long time. This was evident when investors from all over the world gathered for two half days at Nasdaq in Stockholm to discuss future joint investments.

For the first time ever, investors were offered “speed dating” when the industry organization SwedenBIO launched the meeting place “vc2vc“. The idea is to facilitate collaborations between different venture capital firms and establish a smoother path with lower thresholds to the Nordic business culture. These are investments in private or listed life science companies.

– The fact that foreign investors can talk exclusively with Nordic investor colleagues makes it easier to reach this market. We are pleased that our new platform for such meetings, vc2vc, has been so well received, says Björn Ursing, program manager at SwedenBIO.

The list of participants includes Nordic venture capital firms such as Healthcap, Industrifonden, Investinor, Novo Seeds, Sunstone, Lundbeckfonden Ventures and Inventure, along with foreign investors such as Forbion Capital Partners, Gilde Healthcare Partners, Hovione Capital and Medicxi.

Together, the investors represented 350 life science companies, and during the “speed dating” session, entire project portfolios and interests in specific companies were discussed, as well as long-term strategies for the future. In total, more than 80 such meetings between different investors took place during the conference.

– The industry organization SwedenBIO works to promote the life science industry in Sweden. Bringing life science investors to a meeting focused on our internationally very prominent research companies in this way is an important step to provide the necessary capital, says Jonas Ekstrand CEO of SwedenBIO.

The meeting was held at Nasdaq Stockholm, which was also one of the co-organizers together with SwedenBIO members Advokatfirman Vinge and Awapatent.

– Nasdaq works continuously with investors, industry organizations and other stakeholders to create the right conditions for companies to grow. Life sciences and biotech are also large and important sectors for Nasdaq, so it was natural for us to support this initiative,” said Adam Kostyál, Head of European Listings at Nasdaq.

At SwedenBIO’s international investor and partnering conference Nordic Life Science Days on September 12-14 in Malmö-Copenhagen, the investors will meet again, but this time together with about 1100 other delegates, most of them from Nordic research and development life science companies.

For more information, please contact Björn Ursing, Program Manager SwedenBIO. at
bjorn.ursing@swedenbio.se
or 070 – 811 12 68.

Facts about the life science industry in Sweden

The life science industry is an important part of Sweden as a research nation. More than 40 000 people are employed in nearly 1500 life science companies in Sweden. Of these, around 800 companies, with 11,000 employees, carry out their own research and development. Life science companies account for around 7 percent of Sweden’s goods exports, which, thanks to their strong R&D presence, also generate significant tax revenues for Sweden.

SwedenBIO is the national trade organization for life sciences in Sweden. Our more than 220 member companies develop biotechnology, diagnostics, pharmaceuticals, and medical devices, or are experts in business development, IP and law.

Read the press release and download high-resolution images here.